GLP-1 receptor agonists in multiple sclerosis: a systematic review of preclinical and clinical evidence.
GLP-1 medications show anti-inflammatory and brain-protective effects in MS animal models, suggesting potential beyond diabetes if clinical evidence emerges.
This systematic review in Multiple Sclerosis and Related Disorders synthesizes preclinical data showing GLP-1 RA anti-inflammatory and neuroprotective effects in MS animal models alongside preliminary clinical observations in MS patients, building the case for GLP-1 RA as a potential disease-modifying therapy in MS. Evidence remains largely preclinical with limited clinical translation to date.
What the study was
- Study design
- systematic_review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Mult Scler Relat Disord
Why it surfaced
GLP-1 RA repurposing for neuroinflammatory disease is an active research frontier; if neurological benefits extend beyond obesity/T2D, the potential therapeutic reach expands enormously; relevant to cardiometabolic watchlist as a pleiotropic GLP-1 signal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.